By their nature, patents create monopolies that the drug may allow prices to remain artificially high. In other areas that could be just a nuisance or an inconvenience, but in the world of drugs, may be a matter of life or death for those who can not afford such inflated prices.

To resolve this problem, several solutions have been proposed, such as price - an example of how it might work for the development of drugs to treat HIV / AIDS was discussed recently at Techdirt. An alternative approach is the use of patent pools. That's how the patent medicines explains the system:

with the common model of patents, there are several patents pooled and approved by a single entity, in order to reduce transaction costs for all parties involved. In the case of drugs, allowing lower-cost versions of patented medicines and adapted more that occur as a generic, well before its 20-year patents run out. Not only does the pool help speed up the process of obtaining badly needed new and better anti-HIV drugs to people in need, at prices much more affordable, but also encourage the development of products that do not necessary exist, as fixed-dose combination of some (FDC), pills containing two or more new drugs in one tablet, appropriate medicines such as those that can be used in hot climates, unrefrigerated, and drugs against HIV for children .

The pool is a model of win-win-win, that patent holders are compensated for sharing their patents, generic access to market makers, and patients receive appropriate medications faster and adapted to more affordable prices.

It's not a question of "expropriate" patents, but the removal of barriers and simplify licensing arrangements, so that everyone wins. Unfortunately, this is not the way Johnson & Johnson sees:

December 19, Johnson & Johnson returned to people living with HIV / AIDS in many developing countries, saying the pool refused to license its patents on the drugs against HIV rilpivirine, darunavir, and etravirine.

Johnson & Johnson is the reason? According to Doctors Without Borders / Medecins Sans Frontieres (MSF):

Johnson & Johnson said there is no urgency for taking these drugs widely available in developing countries. This is simply not true. MSF treats more than 180,000 people living with HIV worldwide, and begins to witness the inevitable, a native of treatment failure, as people develop resistance to drugs you are taking and the need to switch to new drugs .

As MSF also notes:

within Johnson & Johnson and other companies to participate in a collective manner before making the drugs available to more people in all developing countries are not part of the solution, because they want the public thinks. They contribute to the problem. They want to control who can and use their drugs based on business needs rather than the needs of people living with HIV.



What makes it particularly frustrating for doctors looking to expand the availability of these drugs is that Johnson & Johnson has a whole section of your main site, entitled "Our Values Credo, "which are summarized below:
Find best price for : --Credo----Johnson--